摘要 : In a recent study published in The New England Journal of Medicine,researchers developed an innovative"all-in-one"treatment protocol that combines CD7^(+) chimeric antigen receptor T-cell therapy with subsequent haploidentical hem... 展开 In a recent study published in The New England Journal of Medicine,researchers developed an innovative"all-in-one"treatment protocol that combines CD7^(+) chimeric antigen receptor T-cell therapy with subsequent haploidentical hematopoietic stem cell transplantation.This approach significantly advances the treatment of CD7^(+)hematological malignancies by eliminating the need for myeloablative chemotherapy and immunosuppressants for graft-versushostdiseaseprophylaxis.Chimeric antigen receptor(CAR)T-cell therapy utilizes synthetic antigen receptors targeting T lymphocytes to attack tumor cells specifically. 收起